$NNOX

Nano X Imaging Ltd (NNOX) (Q2 2026) Earnings Call Highlights: Re

Nano X Imaging Ltd (NNOX) reported a 37% year-over-year revenue increase in Q2 2026, driven by growth in teleradiology services and new partnerships. The company also announced operational streamlining and cost reductions. However, NNOX recorded a $40.7 million impairment charge, a significant decrease in cash position, and a widened net loss of $55.5 million. Management expects revenue traction in the coming months and potential market expansion due to new reimbursement codes.

Original reporting
Published Sep 9, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 11:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NNOX
Bearish
medium confidence
Mentioned
$NNOX
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$NNOXBearishMed
01

Why it matters

The earnings release provides fresh data on revenue, impairment, cash position, and cost‑saving initiatives, informing short‑term trading decisions.

02

Market read

The report is material for investors tracking micro‑cap health‑tech stocks, especially those with exposure to AI‑driven imaging and cash‑flow risk.

03

What to watch

Potential upside from new distribution partnerships and reimbursement pathways not yet reflected in price.

Relevance 7/10Novelty 8/10Timing: post‑earnings Q2 2026 release

Background

Nano X Imaging Ltd (NNOX) reported its Q2 2026 results, showing strong revenue growth but significant losses and cash depletion.

Company-level read

Ticker impact

$NNOXBearishMedium confidence
Context

Q2 2026 earnings call disclosed 37% YoY revenue growth, a $40.7M non‑cash impairment, cash down to $31.4M and a $2M cost‑saving plan for 2027.

Expected impact

Potential near‑term downside pressure unless guidance improves; long‑term upside if cost cuts succeed.

Evidence & confidence

Revenue growth is positive, but the large impairment and cash depletion suggest liquidity concerns that could weigh on the stock.

Market effects

Highlights challenges for small‑cap medical imaging firms balancing growth and cash burn.

South Korea operations restructuring may affect regional suppliers.

Limited to niche imaging and AI‑driven diagnostics sector.

Counterpoint

Cost‑cutting and new CMS code could enable a turnaround if execution improves.

Key entities

  • Erez Meltzer

    Provided commentary on revenue outlook and reimbursement code impact.

  • Guy Nathanzon

    Discussed impairment charge and cost‑saving plan.

Related articles

$NNOXHigh

Nano-X Imaging Ltd. (NNOX): Financial results for Q2 2026

Nano-X Imaging Ltd. (NNOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates Management to host conference call and webcast on Wednesday, September 9, 2026 at 8:30 AM ET PETACH TIKVA, Israel — September 9, 2026 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or

$NNOXMed

NANO-X IMAGING LTD: Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom

Nanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.

$CCLMedAI 8/10

Carnival Is Still Down 18% This Year: Did Today Just Mark the Bottom?

Carnival (CCL) stock rose 14% to $25.17 after beating Q2 earnings and revenue estimates, but remains down 18% YTD. The company reported record customer deposits of $7.6B, indicating strong forward demand. Competitors Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH) are down 6% and 34% YTD, respectively. Energy costs remain a pressure point for the industry.

$JEFMed

Jefferies Beats Estimates but BMO Lowers Its Target Anyway

BMO Capital cut its Jefferies Financial Group (JEF) price target to $50 from $57, maintaining a Market Perform rating. The bank reported Q3 adjusted EPS of $1.08, beating BMO's estimate of $1.05 and the consensus of $1.00. Shares were down 1.38% intraday. BMO noted mixed performance across business segments, with equities trading and investment banking outperforming, while fixed income and equity capital markets underperformed.